NeoImmuneTech Management

Management criteria checks 1/4

We currently do not have sufficient information about the CEO.

Key information

Luke Yun Oh

Chief executive officer

n/a

Total compensation

CEO salary percentage	n/a
CEO tenure	less than a year
CEO ownership	n/a
Management average tenure	3.2yrs
Board average tenure	1.8yrs

Recent management updates

Recent updates

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

Mar 22

CEO

Luke Yun Oh

less than a year

Tenure

Dr. Luke Yun Suk Oh Ph. D. is President of NeoImmuneTech, Inc. from January 15, 2024 and serves as its Chief Executive Officer since March 29, 2024 and serves as its Chairman since 2024. Dr. Oh is an exper...

Leadership Team

Name	Position	Tenure	Compensation	Ownership
Luke Yun Oh	President	less than a year	no data	no data
Tae Woo Kim	Chief Financial Officer	no data	no data	0% ₩ 0
Goongjin Nam	Chief Operating Officer	4.3yrs	no data	0% ₩ 0
Byung Lee	Chief Scientific Officer	3.2yrs	no data	0% ₩ 0

3.2yrs

Average Tenure

Experienced Management: A950220's management team is considered experienced (3.2 years average tenure).

Board Members

Name	Position	Tenure	Compensation	Ownership
Luke Yun Oh	President	less than a year	no data	no data
Rafi Ahmed	Member of Scientific Advisory Board	4.5yrs	no data	no data
Soo-Hyoung Kang	Director	no data	no data	no data
Jin-Hyoung Kang	Director	3yrs	no data	no data
Sung-June Hong	Director	less than a year	no data	no data
Richard Kim	Member of Scientific Advisory Board	1.8yrs	no data	no data
Keith Watson	Member of Scientific Advisory Board	1.8yrs	no data	no data
Hyunseok Kang	Member of Scientific Advisory Board	1.8yrs	no data	no data
Young Chae	Member of Scientific Advisory Board	1.8yrs	no data	no data
Benny Chen	Member of Scientific Advisory Board	less than a year	no data	no data
Su-Hyung Park	Member of Scientific Advisory Board	less than a year	no data	no data
Choonggoo Kang	Director	less than a year	no data	no data

1.8yrs

Average Tenure

Experienced Board: A950220's board of directors are not considered experienced ( 1.8 years average tenure), which suggests a new board.

NeoImmuneTech Management

Management criteria checks 1/4

Key information

Recent management updates

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Appoints Luke Oh as President

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

Recent updates

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

NeoImmuneTech, Inc. Announces Chief Executive Officer Changes

Will NeoImmuneTech (KOSDAQ:950220) Spend Its Cash Wisely?

New minor risk - Share price stability

NeoImmuneTech, Inc. Appoints Luke Oh as President

Fda Grants Orphan Drug Designation to Neoimmunetech's Nt-I7 for the Treatment of Acute Radiation Syndrome

New minor risk - Share price stability

Neoimmunetech, Inc. Appoints Benny J. Chen and Su-Hyung Park to Its Scientific Advisory Board

No independent directors

New Evidence of NeoImmuneTech's NT-I7 Clinical Efficacy in Combination with Pembrolizumab in Relapsed/Refractory (R/R) Gastrointestinal Tumors

NeoImmuneTech, Inc. Appoints New Members to its Scientific Advisory Board

NeoImmuneTech's NT-I7 Enhances CAR-T Cell Expansion, Persistence and Anti-tumor Activity

NeoImmuneTech, Inc.'s Lead Asset NT-I7 (efineptakin alfa) Shows Preliminary Anticancer Activity in Combination with Check-Point Inhibitors

No independent directors

Neoimmunetech Demonstrates Nt-I7’S Broad Combination Potential with Immune Checkpoint Inhibitors and Immunocytokine At Aacr 2022

NeoImmuneTech, Inc. Announces First Patient Dosed in Phase 2 Study of NT-I7 (efineptakin alfa) with PD-L1 Checkpoint Inhibitor in High-Risk Skin Cancers

NeoImmuneTech, Inc. Announces the Publication of Preclinical Data Evaluating Lead Asset NT-I7

NeoImmuneTech, Inc. announced that it has received $4.7 million in funding from Hefei SPARK Venture Capital Management Co., Ltd., Kindstar Global (Beijing) Technology, Inc.

NeoImmuneTech, Inc. Presents Phase 1 Study Data at Society for Neuro-Oncology Annual Meeting

Neoimmunetech to Present At Society for Neuro-Oncology

NeoImmuneTech Receives U.S. FDA IND Clearance for Phase 1 Study of NT-I7 (efineptakin alfa) for the Treatment of Kaposi Sarcoma in Patients With or Without HIV Infection

NeoImmuneTech, Inc. Announces First Clinical Trial Application Authorization Received in the EU for its Phase 2 Study of NT-I7 (efineptakin alfa) and Opdivo® (nivolumab)

NeoImmuneTech, Inc. Announces First Patient Dosed in the Pilot Study of NT-I7 (efineptakin alfa) in Progressive Multifocal Leukoencephalopathy

CEO

Tenure

Leadership Team

Average Tenure

Board Members

Average Tenure